TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02492074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration of placebo
Study: NCT06157944

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPT-4
Description: OpenAI's GPT-4 large language model with chat interface.
Study: NCT06400732

Intervention type: DEVICE
Intervention: Fitbone Transport and Lengthening System
Description: Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
Study: NCT05390541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered to Test Yourself
Description: There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
Study: NCT05127889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curodont
Description: * To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.
Study: NCT05306301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
Study: NCT05787691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised pain management
Description: TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants.
Study: NCT05003076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of Methamphetamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of Methamphetamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be given a placebo capsule that will only contain lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT04857645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusions
Description: In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
Study: NCT03923582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive sexual health curriculum
Description: This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations.
Study: NCT04835376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis
Description: Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis
Description: Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis
Description: Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
Study: NCT05277662

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cell and molecular diagnostics in accordance with functional test results
Description: Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1).
Study: NCT05176444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
Study: NCT05980689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: During neo-CRT: 2 cycles of AK104, 10mg/kg d1 q3w. After neo-CRT: 3 cycles of AK104, 10mg/kg d1 q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During neo-CRT: 825mg/m2 bid Monday-Friday per week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy
Description: IMRT DT: 50Gy/25Fx
Study: NCT05901779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules
Description: Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
Study: NCT04962633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Pasta
Description: Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Pasta
Description: Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
Study: NCT04862845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine and Pregabalin
Description: will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Description: received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
Study: NCT06219850

Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.

Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.

Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.

Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.

Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.

Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
Study: NCT06478160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Blood Sampling Devices
Description: blood collection with Closed-Blood Sampling System (CBSD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waste discard volume
Description: Blood collection without CBSD, usual practice, need to waste discard volume
Study: NCT04731168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Patients will have a mandibular advancement device during the first postoperative night
Study: NCT04342039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Nasal
Description: budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sprays each nostril daily on days as indicated in the timeline
Study: NCT04834947

Intervention type: PROCEDURE
Intervention: prone position
Description: Choice of prone positioning a patient is at the discretion of the anesthesia physician.
Study: NCT05741515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Balance Therapy
Description: see intervention arm description

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: see sham intervention arm description
Study: NCT04501367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4 mg
Description: To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4 mg
Description: To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone acetate 1%
Description: To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
Study: NCT06537154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Surveillance
Description: Participant found to have a cCR will be randomized to either standard of care or investigational active surveillance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control arm - Definitive bladder treatment
Description: Standard of care, consisting of radical cystectomy or chemo-radiation of the bladder
Study: NCT06422260

Intervention type: OTHER
Intervention: Prosthesis superstructure
Description: Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials

Intervention type: OTHER
Intervention: Prosthesis superstructure
Description: Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials

Intervention type: OTHER
Intervention: Prosthesis superstructure
Description: Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
Study: NCT06014489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: during run-in and extention phase: from Cycle 1 until relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: during run-in and extention phase: from Cycle 1 until relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse
Study: NCT05485766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID (twice daily) orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgery
Description: Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
Study: NCT04969120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9 sodium chloride)
Description: this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
Study: NCT05815472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit charge
Description: Internet of Things Technologies Device
Study: NCT04588792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Furosemide
Description: Furosemide administered by nebulization through the ventilator circuit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Saline
Description: Saline administered by nebulization through the ventilator circuit
Study: NCT05325450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Program A
Description: Presentation of the sentence to the implant alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Program B
Description: Presentation of the sentence to the implanted ear, associated for the non-implanted ear

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
Study: NCT04892888

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: COVID-19 Vaccine Intramuscular Injection
Study: NCT06027853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLL1 CAR-NK cell injection
Description: Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent
Study: NCT04678154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin and Tobramycin
Description: The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
Study: NCT06242314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L_PRF
Description: Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Palatal stent
Description: Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
Study: NCT06536803

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
Description: high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-load strength training with routine physiotherapy
Description: high load strength training with routine physiotherapy for 12 weeks
Study: NCT05245760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Tislelizumab
Description: Participants will receive 200mg, every three weeks for up to 51 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated radiation
Description: Concurrent with chemo, x5 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Surgical resection of cancer after chemoradiation therapy when no disease progression found.
Study: NCT05200533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-sharing and shifting model between family physicians and physiotherapists
Description: Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Medical consultations for acute low back pain patients are performed by family physicians